Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

 Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Shots:

  • The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India
  • The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform
  • Additionally, NeuClone and Serum Institute are developing eight other biosimilars including clinical-stage candidates referencing Stelara (ustekinumab) and Herceptin (trastuzumab)

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Daily

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post